- Home
- ISPC vs TOVX Comparison
ISPC vs TOVX Comparison
Compare ISPC & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ISPC
- TOVX
- Stock Information
- Founded
- ISPC 2009
- TOVX 2001
- Country
- ISPC United States
- TOVX United States
- Employees
- ISPC N/A
- TOVX N/A
- Industry
- ISPC Precision Instruments
- TOVX Biotechnology: Pharmaceutical Preparations
- Sector
- ISPC Health Care
- TOVX Health Care
- Exchange
- ISPC Nasdaq
- TOVX Nasdaq
- Market Cap
- ISPC 4.6M
- TOVX 4.5M
- IPO Year
- ISPC 2021
- TOVX 2006
- Fundamental
- Price
- ISPC $0.82
- TOVX $0.42
- Analyst Decision
- ISPC
- TOVX Hold
- Analyst Count
- ISPC 0
- TOVX 1
- Target Price
- ISPC N/A
- TOVX N/A
- AVG Volume (30 Days)
- ISPC 1.3M
- TOVX 1.2M
- Earning Date
- ISPC 08-14-2025
- TOVX 08-11-2025
- Dividend Yield
- ISPC N/A
- TOVX N/A
- EPS Growth
- ISPC N/A
- TOVX N/A
- EPS
- ISPC N/A
- TOVX N/A
- Revenue
- ISPC $5,908,088.00
- TOVX N/A
- Revenue This Year
- ISPC $35.93
- TOVX N/A
- Revenue Next Year
- ISPC N/A
- TOVX N/A
- P/E Ratio
- ISPC N/A
- TOVX N/A
- Revenue Growth
- ISPC N/A
- TOVX N/A
- 52 Week Low
- ISPC $0.70
- TOVX $0.37
- 52 Week High
- ISPC $8.30
- TOVX $7.15
- Technical
- Relative Strength Index (RSI)
- ISPC 35.91
- TOVX 44.90
- Support Level
- ISPC $1.13
- TOVX $0.45
- Resistance Level
- ISPC $1.50
- TOVX $0.47
- Average True Range (ATR)
- ISPC 0.20
- TOVX 0.04
- MACD
- ISPC -0.06
- TOVX 0.00
- Stochastic Oscillator
- ISPC 11.11
- TOVX 31.76
About ISPC iSpecimen Inc.
iSpecimen Inc is a technology-driven company focused on connecting life science researchers who need human biofluids, solid tissues, and hematopoietic stem and immune cells for their research, with the available biospecimens. The company generates revenue by procuring various specimens from hospitals, laboratories, and other supply sites. Geographically, it has a presence in the Americas; Europe, the Middle East, Africa, and Asia Pacific, which majority, comes from the Americas.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.